Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

Abstract Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and Hemostasis recommends avoiding the use of direct oral anticoagulants (DOAC)s in morbidly obese pat...

Full description

Bibliographic Details
Main Authors: Khalid Al Sulaiman, Hisham A. Badreldin, Ghazwa B. Korayem, Abeer A. Alenazi, Faisal Alsuwayyid, Abdulrahman Alrashidi, Mohammed Alhijris, Faisal Almutairi, Fahad Alharthi, Ramesh Vishwakarma, Omar Al Shaya, Abdulrahman Al Amri, Saqiba Tayyab, Abdulkareem M. Al Bekairy, Ohoud Aljuhani
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Thrombosis Journal
Subjects:
Apixaban
Morbidly obese
BMI ≥ 40
Atrial fibrillation
Thrombosis
Bleeding
Online Access:https://doi.org/10.1186/s12959-022-00379-x

Internet

https://doi.org/10.1186/s12959-022-00379-x

Similar Items